MiNK Therapeutics, Inc. announced Barbara Ryan was appointed to it's board of directors and chairs the Audit Committee. Ms. Ryan brings over 40 years of experience in the biopharmaceutical industry and capital markets. Dr. Mark Exley joined MiNK's scientific advisory board as a leading expert and pioneer in iNKT cell biology.

Dr. Exley has led the characterization of human natural killer cells, inflammatory immune responses to viral infections, and cells involved in suppressing graft-versus-host disease. Dr. Bob Stein was appointed to join the it's scientific advisory board, bringing over 35 years of experience in the biopharmaceutical industry. Over the course of his career, Dr. Stein has played a significant role in the discovery and development of eight marketed drugs, including SUSTIVA®, FABLYN®, VIVIANT®, PanRetin®, TargRetin®, PROMACTA®, and ELIQUIS®.